市場調查報告書

IgG4相關疾病:市場洞察,流行病學,到2028年前的市場預測

IgG4-Related Disease-Market Insights, Epidemiology, and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 905940
出版日期 內容資訊 英文 135 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
IgG4相關疾病:市場洞察,流行病學,到2028年前的市場預測 IgG4-Related Disease-Market Insights, Epidemiology, and Market Forecast - 2028
出版日期: 2019年08月01日內容資訊: 英文 135 Pages
簡介

本報告提供全球IgG4相關疾病市場的相關調查,提供市場趨勢,成長要素,規模預測,美國·德國·法國·義大利·西班牙·英國·日本等7個國家的市場分析等資訊。

目錄

第1章 重要的洞察

第2章 IgG4相關疾病市場概要

  • 2017年的市場佔有率(%)分佈
  • 2028年的市場佔有率(%)分佈

第3章 疾病的背景及概要:IgG4相關疾病

  • 簡介
  • 免疫球蛋白
  • 臨床症狀
  • 病理學的機制
  • 症狀
  • 器官系統參與的臨床特徵
  • 病理生理學
  • IgG4相關疾病的病因
  • 診斷

第4章 流行病學及患者人口

  • 主要調查結果
  • 主要7個國家的患者總數
  • 主要7個國家的整體診斷患者數

第5章 IgG4相關疾病:各國流行病學

  • 美國
    • 假設及根據
    • 盛行率
    • 確診的盛行率
    • 性別的盛行率
    • 自體免疫性胰炎(AIP)的盛行率
  • 歐洲主要5國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 治療

  • 糖皮質激素
    • 誘導療法
    • 維持療法
  • IgG4-RD的傳統「緩解疾病性抗風濕藥」(DMARD)
    • IgG4-RD的B細胞標靶治療
    • 治療標的的性狀芽細胞
  • 糖皮質激素節約劑
  • 替代方案
  • 今後的治療方針
    • CD4 + CTL治療
    • 抗纖維化療法
    • 最近的進步

第7章 IgG4相關疾病的管理及治療相關國際協定指導

  • 聲明1:患者的評估
    • 血清學的檢驗
    • 其他實驗室標記
    • 放射線科
  • 聲明2:治療前的組織確認
  • 聲明3:治療的適應症
    • 緊急治療
    • 治療的其他誘因
    • 高纖維性病變
  • 聲明4:糖皮質激素緩解誘導
  • 聲明5:類固醇節約劑的使用
    • 傳統的類固醇保留劑
    • B細胞耗盡作為類固醇保留方法
  • 聲明6:緩解誘導後使用維持治療
  • 聲明7:控制疾病復發

第8章 潛在的需求

第9章 新藥

  • 主要的競爭
  • Obexelimab (XmAb5871): Xencor
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 產品簡介
  • Abatacept: Bristol-Myer Squibb

第10章 IgG4相關的病:7個主要的市場分析

  • 主要調查結果
  • 主要7個國家的市場規模

第11章 美國:市場預測

  • 美國的市場規模
    • IgG4相關疾病的整體市場規模
    • 各療法市場規模

第12章 歐盟五國:市場預測

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國

第13章 日本:市場預測

  • 日本市場規模

第14章 市場成長要素

第15章 市場障礙

第16章 附錄

  • 報告方法

第17章 DelveInsight的服務內容

第18章 免責聲明

第19章 關於DelveInsight

目錄
Product Code: DIMI0671

DelveInsight's 'IgG4-Related Disease-Market Insights, Epidemiology, and Market Forecast--2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of IgG4-Related Disease in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of IgG4-Related Disease from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

IgG4-Related Disease - Disease Understanding and Treatment Algorithm

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory disease characterized by dense infiltration of IgG4-positive plasma cells in the affected tissue(s) with or without elevated plasma levels of IgG4. It is a chronic-fibroinflammatory disorder affecting a wide range of organs. Elevation of serum IgG4 concentrations and abundant infiltration of IgG4-expressing plasma cells are key diagnostic features of this autoimmune disease. Although common organ involvement of IgG4-RD includes the salivary glands, pancreas, and bile duct, hepatic involvement is less well established. IgG4RD may be present in a certain proportion of patients with a wide variety of diseases, including Mikulicz's disease, autoimmune pancreatitis, hypophysitis, Riedel thyroiditis, interstitial pneumonitis, interstitial nephritis, prostatitis, lymphadenopathy, retroperitoneal fibrosis, inflammatory aortic aneurysm, and inflammatory pseudotumor.

The diagnostic workup of IgG4-RD is complex and usually requires a combination of clinical examination, imaging, histological, and serological analyses. However, no finding alone is specific for IgG4-RD. Therefore, its diagnosis requires careful interpretation of examination results in context with the patient's clinical appearance as well as the exclusion of a broad variety of differential diagnoses.

The DelveInsight IgG4-Related Disease market report gives the thorough understanding of the IgG4-Related Disease by including details, such as disease introduction, immunoglobulins, clinical manifestations, pathophysiological mechanisms, symptoms, clinical Features of Organ system involvement, pathophysiology, the pathogenesis of IgG4-related disease and diagnosis. It also provides treatment algorithms and treatment guidelines for IgG4-Related Disease in the US, Europe, and Japan.

IgG4-Related Disease Epidemiology

According to the American College of Rheumatology, IgG4 related disease tends to affect middle-aged to elderly individuals. Unlike many autoimmune diseases, IgG4-RD tends to affect males more often than females. Some patients have levels of IgG4 in their blood that are 20 or 30 times higher than the upper limit of normal. In a significant minority of patients, however, the serum IgG4 concentration is normal. The organs that are often involved in IgG4-RD include meninges, orbits, lacrimal glands, major salivary glands, thyroid gland, lungs, aorta, kidneys, pancreas, and bile ducts.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of IgG4-Related Disease in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2028 for the following aspects:

  • Prevalent Population of IgG4-Related Disease
  • Diagnosed Prevalent Population of IgG4-Related Disease
  • Gender-specific Prevalent Population of IgG4-RD
  • Diagnosed Prevalent Population of Autoimmune Pancreatitis (AIP)

As per a study conducted by Gervasio et al. titled "IgG4-related Orbital Inflammation" stated that the incidence of IgG4-ROD had been reported between 5% and 20% among inflammatory orbital lesions. It was also the lacrimal gland being the most commonly involved site in IgG4-ROD, i.e., approximately 62-88%. Other common sites included the trigeminal nerve, i.e., approximately 9.5-39%, extraocular muscles 19-25%, orbital fat 28.6-40%, eyelid 12% and the nasolacrimal duct system 1.5-9.5. While, less commonly, IgG4-ROD may affect the sclera. Also, IgG4-RD, particularly AIP, tends to occur more often in older males compared to females associated with salivary gland lesions and a higher serum IgG4 level.

According to a study conducted by Yamamoto et al. titled "Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist" stated that the number of patients with IgG4-related disease was estimated to be about 8000 in Japan, including around 4300 patients with IgG4-related dacryoadenitis and sialadenitis and 2700 patients with type 1 AIP. In addition, the average age of disease onset was in the seventh decade of life, with the gender ratio showing a predisposition of IgG4-related disease in men.

IgG4-Related Disease Drug Chapters

This segment of the IgG4-Related Disease report encloses the detailed analysis of late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

To meet the increasing demand for the treatment of IgG4-Related Disease, companies have shifted their focus toward the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of IgG4-Related Disease and awareness of the disease. The overall dynamics of IgG4-Related Disease market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players, such as Xencor and Bristol-Myer Squibb will significantly increase the market during the forecast period (2019-2028).

IgG4-Related Disease Market Outlook

IgG4-related disease (IgG4-RD) is a systemic fibro inflammatory disease characterized by dense infiltration of IgG4-positive plasma cells in the affected tissue(s) with or without elevated plasma levels of IgG4. Some patients with asymptomatic IgG4-RD can be watched without treatment, e.g., asymptomatic lymphadenopathy or mild submandibular gland enlargement. Special attention should be made to active IgG4-RD in the pancreas, biliary tree, aorta, mediastinum, kidneys, retroperitoneum, and mesentery as in those cases starting therapy is urgent that must be considered.

There are no specific drugs available that cure the disease completely as the pathophysiology of the IgG4-related disease is not clear and still under research and development. Currently, the market holds no approved therapies for patients with IgG4-related diseases. According to the recent guidelines published by "International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease," which explained the criteria for determining the type of disease caused due to IgG4 levels and the treatment guidelines for the patients. The commonly used treatment options include Glucocorticoids, Immunomodulators, and Rituximab.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of IgG4-Related Disease in 7MM is expected to change from 2019 to 2028.

IgG4-Related Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allowing the comparison of the drugs on the basis of market share and size will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for IgG4-Related Disease such as XmAb5871 (Xencor) and Abatacept (Bristol-Myer Squibb) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the IgG4-Related Disease market.

IgG4-Related Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

IgG4-Related Disease Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

IgG4-Related Disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the IgG4-Related Disease market.
  • Organize sales and marketing efforts by identifying the best opportunities for IgG4-Related Disease market.
  • To understand the future market competition in the IgG4-Related Disease market.

Table of Contents

1. Key Insights

2. IgG4-Related Disease Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of IgG4-Related Disease in 2017
  • 2.2. Market Share (%) Distribution of IgG4-Related Disease in 2028

3. Disease Background and Overview: IgG4-Related Disease

  • 3.1. Introduction
  • 3.2. Immunoglobulins
  • 3.3. Clinical Manifestations
  • 3.4. Pathophysiological Mechanisms
  • 3.5. Symptoms
  • 3.6. Clinical Features of Organ System Involvement
  • 3.7. Pathophysiology
  • 3.8. Pathogenesis of IgG4-related disease
  • 3.9. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM IgG4-Related Disease Total Patient Population
  • 4.3. 7MM IgG4-Related Disease Total Diagnosed Patient Population

5. Country Wise-Epidemiology of IgG4-Related Disease

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. IgG4-Related Disease (IgG4-RD) Prevalent Population in the United States
    • 5.1.3. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in the United States
    • 5.1.4. IgG4-RD Gender-specific Prevalent Population in the United States
    • 5.1.5. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United States
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
  • 5.3. Germany
    • 5.3.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in Germany
    • 5.3.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Germany
    • 5.3.3. IgG4-RD Gender-specific Prevalent Population in Germany
    • 5.3.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Germany
  • 5.4. France
    • 5.4.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in France
    • 5.4.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in France
    • 5.4.3. IgG4-RD Gender-specific Prevalent Population in France
    • 5.4.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in France
  • 5.5. Italy
    • 5.5.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in Italy
    • 5.5.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Italy
    • 5.5.3. IgG4-RD Gender-specific Prevalent Population in Italy
    • 5.5.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Italy
  • 5.6. Spain
    • 5.6.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in Spain
    • 5.6.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Spain
    • 5.6.3. IgG4-RD Gender-specific Prevalent Population in Spain
    • 5.6.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Spain
  • 5.7. United Kingdom
    • 5.7.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in the United Kingdom
    • 5.7.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in the United Kingdom
    • 5.7.3. IgG4-RD Gender-specific Prevalent Population in the United Kingdom
    • 5.7.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United Kingdom
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. IgG4-Related Disease (IgG4-RD) Prevalent Population in Japan
    • 5.8.3. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Japan
    • 5.8.4. IgG4-RD Gender-specific Prevalent Population in Japan
    • 5.8.5. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Japan

6. Treatment

  • 6.1. Glucocorticoids
    • 6.1.1. Induction Therapy
    • 6.1.2. Maintenance therapy
  • 6.2. Conventional "Disease-Modifying Anti-Rheumatic Drugs" (DMARDs) in IgG4-RD
    • 6.2.1. B Cell-Targeted Therapy in IgG4-RD
    • 6.2.2. Plasmablasts as a target of treatment
  • 6.3. Glucocorticoids sparing agents
  • 6.4. Alternative methods
  • 6.5. Future Therapeutic Directions
    • 6.5.1. CD4+ CTL-directed treatments
    • 6.5.2. Anti-fibrosis Therapies
    • 6.5.3. Recent Advancement

7. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Diseases

  • 7.1. Statement 1: Patient evaluation
    • 7.1.1. Serologic testing
    • 7.1.2. Other laboratory markers
    • 7.1.3. Radiology
  • 7.2. Statement 2: Tissue confirmation prior to treatment
  • 7.3. Statement 3: Indications for therapy
    • 7.3.1. Urgent treatment
    • 7.3.2. Other triggers for therapy
    • 7.3.3. Highly fibrotic lesions
  • 7.4. Statement 4: Remission induction with glucocorticoids
  • 7.5. Statement 5: The use of steroid-sparing agents
    • 7.5.1. Conventional steroid-sparing medications
    • 7.5.2. B cell depletion as a steroid-sparing approach
  • 7.6. Statement 6: The use of maintenance therapy following remission induction
  • 7.7. Statement 7: Managing disease relapse

8. Unmet needs

9. Emerging Drugs

  • 9.1. Key Cross Competition
  • 9.2. Obexelimab (XmAb5871): Xencor
    • 9.2.1. Product Description
    • 9.2.2. Other Developmental Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Product Profile
  • 9.3. Abatacept: Bristol-Myer Squibb
    • 9.3.1. Product Description
    • 9.3.2. Clinical Development
    • 9.3.3. Product Profile

10. IgG4-Related Disease: 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Size of IgG4-Related Disease in the 7MM

11. The United States Market Outlook

  • 11.1. United States Market Size
    • 11.1.1. Total Market size of IgG4-Related Disease
    • 11.1.2. Market Size by Therapies

12. EU-5 Countries: Market Outlook

  • 12.1. Germany
    • 12.1.1. Total Market size of IgG4-Related Disease in Germany
    • 12.1.2. Market Size by Therapies
  • 12.2. France
    • 12.2.1. Total Market Size of IgG4-Related Disease
    • 12.2.2. Market Size by Therapies
  • 12.3. Italy
    • 12.3.1. Total Market Size of IgG4-Related Disease
    • 12.3.2. Market Size by Therapies
  • 12.4. Spain
    • 12.4.1. Total Market Size of IgG4-Related Disease
    • 12.4.2. Market Size by Therapies
  • 12.5. United Kingdom
    • 12.5.1. Total Market Size of IgG4-Related Disease
    • 12.5.2. Market Size by Therapies

13. Japan: Market Outlook

  • 13.1. Japan market Size
    • 13.1.1. Total Market Size of IgG4-Related Disease
    • 13.1.2. Market Size by Therapies

14. Market Drivers

15. Market Barriers

16. Appendix

  • 16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1 IgG4-Related Disease Total Population in the 7MM (2017-2028)
  • Table 2 IgG4-Related Disease Total Diagnosed Population in the 7MM (2017-2028)
  • Table 3 IgG4-RD Prevalent Population of IgG4-RD in the United States (2017-2028)
  • Table 4 IgG4-RD Diagnosed Prevalent Population in the United States (2017-2028)
  • Table 5 IgG4-RD Gender-specific Prevalent Population in the United States (2017-2028)
  • Table 6 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United States (2017-2028)
  • Table 7 IgG4-RD Prevalent Population of IgG4-RD in Germany (2017-2028)
  • Table 8 IgG4-RD Diagnosed Prevalent Population in Germany (2017-2028)
  • Table 9 IgG4-RD Gender-specific Prevalent Population in Germany (2017-2028)
  • Table 10 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Germany (2017-2028)
  • Table 11 IgG4-RD Prevalent Population of IgG4-RD in France (2017-2028)
  • Table 12 IgG4-RD Diagnosed Prevalent Population in France (2017-2028)
  • Table 13 IgG4-RD Gender-specific Prevalent Population in France (2017-2028)
  • Table 14 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in France (2017-2028)
  • Table 15 IgG4-RD Prevalent Population of IgG4-RD in Italy (2017-2028)
  • Table 16 IgG4-RD Diagnosed Prevalent Population in Italy (2017-2028)
  • Table 17 IgG4-RD Gender-specific Prevalent Population in Italy (2017-2028)
  • Table 18 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Italy (2017-2028)
  • Table 19 IgG4-RD Prevalent Population of IgG4-RD in Spain (2017-2028)
  • Table 20 IgG4-RD Diagnosed Prevalent Population in Spain (2017-2028)
  • Table 21 IgG4-RD Gender-specific Prevalent Population in Spain (2017-2028)
  • Table 22 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Spain (2017-2028)
  • Table 23 IgG4-RD Prevalent Population of IgG4-RD in the United Kingdom (2017-2028)
  • Table 24 IgG4-RD Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Table 25 IgG4-RD Gender-specific Prevalent Population in the United Kingdom (2017-2028)
  • Table 26 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Table 27 IgG4-RD Prevalent Population of IgG4-RD in Japan (2017-2028)
  • Table 28 IgG4-RD Diagnosed Prevalent Population in Japan (2017-2028)
  • Table 29 IgG4-RD Gender-specific Prevalent Population in Japan (2017-2028)
  • Table 30 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Japan (2017-2028)
  • Table 31 International consensus guidance statements on the treatment of IgG4-related disease (IgG4-RD), voting agreement, level of evidence, and citations
  • Table 32 Comparison of Emerging Drugs Under Development
  • Table 33 Obexelimab (XmAb5871), Clinical Trial Description
  • Table 34 Abatacept, Clinical Trial Description
  • Table 35 7 Major Market Size of IgG4-Related Disease in USD Million (2017-2028)
  • Table 36 United States Market Size of IgG4-Related Disease , USD Million (2017-2028)
  • Table 37 Market size of IgG4-Related Disease by therapies in the United States, in USD Million (2017-2028)
  • Table 38 Market Size of IgG4-Related Disease in Germany, in USD Million (2017-2028)
  • Table 39 Market size of IgG4-Related Disease by therapies in Germany, in USD Million (2017-2028)
  • Table 40 Market Size of IgG4-Related Disease in France, in USD Million (2017-2028)
  • Table 41 Market size of IgG4-Related Disease by therapies in France, in USD Million (2017-2028)
  • Table 42 Market Size of IgG4-Related Disease in Italy, in USD Million (2017-2028)
  • Table 43 Market size of IgG4-Related Disease by therapies in Italy, in USD Million (2017-2028)
  • Table 44 Market Size of IgG4-Related Disease in Spain, in USD Million (2017-2028)
  • Table 45 Market size of IgG4-Related Disease by therapies in Spain, in USD Million (2017-2028)
  • Table 46 Market Size of IgG4-Related Disease in the UK, in USD Million (2017-2028)
  • Table 47 Market size of IgG4-Related Disease by therapies in the United Kingdom, in USD Million (2017-2028)
  • Table 48 Market Size of IgG4-Related Disease in Japan, in USD Million (2017-2028)
  • Table 49 Market size of IgG4-Related Disease by therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1 Pathogenesis of IgG4-RD
  • Figure 2 Comprehensive diagnostic criteria for IgG4-RD
  • Figure 3 Diagnostic algorithm for IgG4-RD
  • Figure 4 IgG4-Related Disease Total Population in the 7MM (2017-2028)
  • Figure 5 IgG4-Related Disease Total Diagnosed Population in the 7MM (2017-2028)
  • Figure 6 IgG4-RD Prevalent Population of IgG4-RD in the United States (2017-2028)
  • Figure 7 IgG4-RD Diagnosed Prevalent Population in the United States (2017-2028)
  • Figure 8 IgG4-RD Gender-specific Prevalent Population in the United States (2017-2028)
  • Figure 9 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United States (2017-2028)
  • Figure 10 IgG4-RD Prevalent Population of IgG4-RD in Germany (2017-2028)
  • Figure 11 IgG4-RD Diagnosed Prevalent Population in Germany (2017-2028)
  • Figure 12 IgG4-RD Gender-specific Prevalent Population in Germany (2017-2028)
  • Figure 13 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Germany (2017-2028)
  • Figure 14 IgG4-RD Prevalent Population of IgG4-RD in France (2017-2028)
  • Figure 15 IgG4-RD Diagnosed Prevalent Population in France (2017-2028)
  • Figure 16 IgG4-RD Gender-specific Prevalent Population in France (2017-2028)
  • Figure 17 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in France (2017-2028)
  • Figure 18 IgG4-RD Prevalent Population of IgG4-RD in Italy (2017-2028)
  • Figure 19 IgG4-RD Diagnosed Prevalent Population in Italy (2017-2028)
  • Figure 20 IgG4-RD Gender-specific Prevalent Population in Italy (2017-2028)
  • Figure 21 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Italy (2017-2028)
  • Figure 22 IgG4-RD Prevalent Population of IgG4-RD in Spain (2017-2028)
  • Figure 23 IgG4-RD Diagnosed Prevalent Population in Spain (2017-2028)
  • Figure 24 IgG4-RD Gender-specific Prevalent Population in Spain (2017-2028)
  • Figure 25 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Spain (2017-2028)
  • Figure 26 IgG4-RD Prevalent Population of IgG4-RD in the United Kingdom (2017-2028)
  • Figure 27 IgG4-RD Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Figure 28 IgG4-RD Gender-specific Prevalent Population in the United Kingdom (2017-2028)
  • Figure 29 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Figure 30 IgG4-RD Prevalent Population of IgG4-RD in Japan (2017-2028)
  • Figure 31 IgG4-RD Diagnosed Prevalent Population in Japan (2017-2028)
  • Figure 32 IgG4-RD Gender-specific Prevalent Population in Japan (2017-2028)
  • Figure 33 Treatment algorithm for IgG4-RD
  • Figure 34 Unmet Needs of IgG4-related diseases
  • Figure 35 7 Major Market Size of IgG4-Related Disease in USD Million (2017-2028)
  • Figure 36 Market Size of IgG4-Related Disease in the United States, USD Millions (2017-2028)
  • Figure 37 Market size of IgG4-Related Disease by therapies in the US, in USD Million (2017-2028)
  • Figure 38 Market Size of IgG4-Related Disease in Germany, USD Million (2017-2028)
  • Figure 39 Market Size of IgG4-Related Disease by therapies, in Germany, in USD Million (2017-2028)
  • Figure 40 Market Size of IgG4-Related Disease in France, USD Million (2017-2028)
  • Figure 41 Market Size of IgG4-Related Disease by therapies, in France, in USD Million (2017-2028)
  • Figure 42 Market Size of IgG4-Related Disease in Italy, USD Million (2017-2028)
  • Figure 43 Market Size of IgG4-Related Disease by therapies, in Italy, in USD Million (2017-2028)
  • Figure 44 Market Size of IgG4-Related Disease in Spain, USD Million (2017-2028)
  • Figure 45 Market Size of IgG4-Related Disease by therapies in Spain, in USD Million (2017-2028)
  • Figure 46 Market Size of IgG4-Related Disease in the UK, USD Million (2017-2028)
  • Figure 47 Market Size of IgG4-Related Disease by therapies in the UK, in USD Million (2017-2028)
  • Figure 48 Market Size of IgG4-Related Disease in Japan, USD Million (2017-2028)
  • Figure 49 Market Size of IgG4-Related Disease by therapies in Japan, in USD Million (2017-2028)
  • Figure 50 Market Drivers
  • Figure 51 Market Barriers
Back to Top